NEXR
Nexera Technologies Ltd
NASDAQ · Healthcare · Biotechnology · IL
$1.70
−4.49%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 26.0M | 16.8M | 13.7M | 10.0M | 5.9M |
| Cost of Revenue | 24.0M | 16.3M | 12.1M | 9.0M | 5.1M |
| Gross Profit | 2.0M | 575.0K | 1.6M | 976.0K | 799.0K |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 12.3M | 8.2M | 5.9M | 5.1M | 5.3M |
| General & Admin Expense | 2.0M | 6.7M | 4.7M | 4.3M | 4.1M |
| Selling & Marketing Expense | 548.0K | 1.5M | 1.2M | 833.0K | 1.2M |
| Other Expenses | 219.0K | (224.0K) | 1.9M | 970.0K | — |
| Total Operating Expenses | 12.5M | 8.0M | 7.8M | 6.1M | 5.3M |
| Cost and Expenses | 36.5M | 24.2M | 19.9M | 15.1M | 10.4M |
| Operating Income (EBIT) | (10.5M) | (7.4M) | (6.2M) | (5.1M) | (4.5M) |
| Non-Operating | |||||
| Interest Income | 184.0K | 100.0K | 78.0K | 4.0K | — |
| Interest Expense | 784.0K | 175.0K | 7.0K | 10.0K | 323.0K |
| Net Interest Income | (600.0K) | (75.0K) | 71.0K | (6.0K) | (323.0K) |
| Other Non-Op Income/Expense | 2.5M | 2.6M | (1.3M) | 523.0K | 2.3M |
| Non-Operating Income (excl Interest) | (81.5K) | — | 1.3M | (523.0K) | (2.6M) |
| EBT (Pre-Tax Income) | (6.9M) | (4.8M) | (7.5M) | (4.6M) | (2.2M) |
| Income Tax Expense | (742.0K) | (736.0K) | 310.0K | 32.0K | (6.0K) |
| Bottom Line | |||||
| Net Income | (5.3M) | (3.7M) | (7.8M) | (4.6M) | (2.2M) |
| Earnings from Cont. Ops | (5.8M) | (4.0M) | (7.8M) | (4.6M) | (2.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (5.3M) | (3.7M) | (7.8M) | (4.6M) | (2.2M) |
| Per Share | |||||
| Basic EPS | ($200.79) | ($81.07) | ($2,835.12) | ($11,729.59) | ($5,916.67) |
| Diluted EPS | ($200.79) | ($81.07) | ($2,835.12) | ($11,729.59) | ($5,916.67) |
| Revenue Per Share | $2.12 | $371.06 | $4,973.84 | $25,530.61 | $15,750.00 |
| Shares | |||||
| Basic Shares Outstanding | 12.2M | 45356 | 2752 | 392 | 372 |
| Diluted Shares Outstanding | 12.2M | 45356 | 2752 | 392 | 372 |
| Profitability Metrics | |||||
| EBITDA | (8.9M) | (6.2M) | (6.7M) | (3.8M) | (1.3M) |
| D&A | 1.6M | 1.2M | 788.0K | 738.0K | 570.0K |
| EBIT | (10.5M) | (7.4M) | (7.5M) | (4.6M) | (1.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026